vedolizumab as a potential culprit in the development of ovarian teratoma?
Clicks: 160
ID: 185575
2017
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
160 views
40 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #43 of 54 articles by views in trends in genetics : tig
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Vedolizumab is a new humanized monoclonal antibody that has been reserved for those with moderate-to-severe Crohn’s disease and ulcerative colitis who have failed immunomodulator and TNF-α antagonist therapy, and for those who have an increased risk for developing progressive multifocal leukoencephalopathy. Because it targets gastrointestinal tract-specific lymphocytes, meta-analyses and integrated studies have shown that vedolizumab causes fewer extraintestinal adverse effects, such as opportunistic infections and malignancies, compared with anti-TNF therapies. We present the case of a patient who developed an ovarian teratoma after initiation of vedolizumab therapy.
| Reference Key |
trieu2017casevedolizumab
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Judy A. Trieu;Mohammad Bilal;Gurinder Luthra |
| Journal | trends in genetics : tig |
| Year | 2017 |
| DOI |
10.1159/000484199
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.